Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Montoro J, Pomares H, Villacampa G, Merchán B, Molero A, Alonso E, Gallur L, Grau J, Salamero O, Roldán E, Saumell S, Ortega M, Sureda A, Bosch F, Arnan M, Valcárcel D. Montoro J, et al. Among authors: villacampa g. Leuk Lymphoma. 2019 Jun;60(6):1522-1527. doi: 10.1080/10428194.2018.1542151. Epub 2018 Nov 30. Leuk Lymphoma. 2019. PMID: 30499738
Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.
Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D. Ortí G, et al. Among authors: villacampa g. Bone Marrow Transplant. 2019 Jul;54(7):1133-1137. doi: 10.1038/s41409-018-0422-z. Epub 2018 Dec 13. Bone Marrow Transplant. 2019. PMID: 30546069 No abstract available.
Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.
Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D. Ortí G, et al. Among authors: villacampa g. Bone Marrow Transplant. 2019 Jul;54(7):1176. doi: 10.1038/s41409-019-0471-y. Bone Marrow Transplant. 2019. PMID: 30733543
Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
Abrisqueta P, Delgado J, Alcoceba M, Oliveira AC, Loscertales J, Hernández-Rivas JA, Ferrà C, Cordoba R, Yáñez L, Medina A, Motlló C, Iacoboni G, Villacampa G, González M, Bosch F. Abrisqueta P, et al. Among authors: villacampa g. Br J Haematol. 2020 Sep;190(6):854-863. doi: 10.1111/bjh.16748. Epub 2020 Jun 9. Br J Haematol. 2020. PMID: 32519351 Free article. Clinical Trial.
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Fox ML, García-Cadenas I, Pérez AM, Villacampa G, Piñana JL, Ortí G, Montoro J, Roldán E, Bosch Vilaseca A, Martino R, Salamero O, Saavedra S, Hernandez-Boluda JC, Esquirol A, Sierra J, Sanz J, Solano C, Bosch F, Barba P, Valcarcel D. Fox ML, et al. Among authors: villacampa g. Leuk Lymphoma. 2020 Aug;61(8):1823-1832. doi: 10.1080/10428194.2020.1788015. Epub 2020 Jul 11. Leuk Lymphoma. 2020. PMID: 32654570
Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant.
Ortí G, Palacio-Garcia C, García-Cadenas I, Sánchez-Ortega I, Jimenez MJ, Azqueta C, Villacampa G, Ferrà C, Parody R, Martino R, Bosch F, Querol S, Valcárcel D. Ortí G, et al. Among authors: villacampa g. Transplant Cell Ther. 2021 Jan;27(1):53.e1-53.e8. doi: 10.1016/j.bbmt.2020.09.024. Epub 2020 Sep 26. Transplant Cell Ther. 2021. PMID: 32987150 Free article.
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Carpio C, Iacoboni G, Villacampa G, Catalá E, Bobillo S, Pérez A, Jiménez M, Segura L, Olivé M, Farriols A, Abrisqueta P, Valcárcel D, Carreras MJ, Bosch F, Barba P. Carpio C, et al. Among authors: villacampa g. Leuk Lymphoma. 2021 Sep;62(9):2288-2291. doi: 10.1080/10428194.2021.1913141. Epub 2021 Apr 24. Leuk Lymphoma. 2021. PMID: 33899648 No abstract available.
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailén R, Lopez Corral L, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Martin Garcia-Sancho A, Kwon M, Reguera-Ortega JL, Barba P; GETH, GELTAMO Spanish Groups. Iacoboni G, et al. Among authors: villacampa g. Cancer Med. 2021 May;10(10):3214-3223. doi: 10.1002/cam4.3881. Epub 2021 May 1. Cancer Med. 2021. PMID: 33932100 Free PMC article.
Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy.
Iacoboni G, Simó M, Villacampa G, Catalá E, Carpio C, Díaz-Lagares C, Vidal-Jordana Á, Bobillo S, Marín-Niebla A, Pérez A, Jiménez M, Abrisqueta P, Bosch F, Barba P. Iacoboni G, et al. Among authors: villacampa g. Ann Hematol. 2021 Sep;100(9):2303-2310. doi: 10.1007/s00277-021-04560-6. Epub 2021 Jul 8. Ann Hematol. 2021. PMID: 34236497
88 results